Treatment of Metastasising GRF-Producing Tumour With a Long-Acting Somatostatin Analogue

Werder, K. Von; Losa, Marco; Müller, Otto; Schweiberer, L.; Fahlbusch, Rudolf; Pozo, E. Del

doi:10.1016/s0140-6736(84)90320-9

Cited by 64 publications

(23 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antiproliferative potency of somatostatin ana logues has been further supported by case reports indicat ing shrinkage or even disappearance of malignant GEP tumors and their metastases [26,[32][33][34][35][36][37]45], These find ings are summarized in table 2.…”

Section: Retrospective Studiesmentioning

confidence: 85%

See 1 more Smart Citation

Management of Gastroenteropancreatic Endocrine Tumors: The Place of Somatostatin Analogues

Arnold

Frank²,

Kajdan³

1994

Digestion

View full text Add to dashboard Cite

The place of the long-acting somatostatin analogue octreotide in the management of symptoms in patients with functional gastroenteropancreatic (GEP) tumors and of growth in patients with metastatic disease is reviewed in this report. Numerous studies indicate that octreotide is, currently, the therapeutic principle of first choice in the symptomatic treatment of patients with carcinoid syndrome, Verner-Morrison syndrome and glucagonoma syndrome but not of insulinoma and gastrinoma patients. A beneficial effect on tumor growth has been demonstrated in 40% of patients with metastatic GEP tumors with stabilization of the disease as the most favorable response. However, further studies have to identify subgroups of patients in whom octreotide alone or in combination with alpha-interferon inhibits tumor growth.

show abstract

Section: Retrospective Studiesmentioning

confidence: 85%

“…Somato statin and its long-acting analogues have been shown to be effective in most but not all of the tumors [25,26].…”

Section: Insulinomamentioning

confidence: 99%

Management of Gastroenteropancreatic Endocrine Tumors: The Place of Somatostatin Analogues

Arnold

Frank²,

Kajdan³

1994

Digestion

View full text Add to dashboard Cite

show abstract

“…. Control of acromegaly in patients with ectopic growth hormone-releasing hormone production by somatostatin analogues (Von Werder et al 1984, Lefebvre et al 1995, Drange & Melmed 1998, Doga et al 2001. .…”

Section: Islet Cell Tumours Of the Pancreas And Carcinoidsmentioning

confidence: 99%

Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas.

Herder

Krenning²,

Eijck³

et al. 2004

Endocr Relat Cancer

View full text Add to dashboard Cite

Endocrine tumours of the gastrointestinal tract and pancreas may present at different disease stages with either hormonal or hormone-related symptoms/syndromes, or without hormonal symptoms. They may occur either sporadically or as part of hereditary syndromes. In the therapeutic approach to a patient with these tumours, excessive hormonal secretion and/or its effects should always be controlled first. Tumour-related deficiencies or disorders should also be corrected. Subsequently, control should be aimed at the tumour growth. Surgery is generally considered as first-line therapy for patients with localized disease, as it can be curative. However, in patients with metastatic disease the role of first-line surgery is not clearly established and other therapies should be considered, such as non-surgical cytoreductive therapies, biotherapy (with somatostatin analogues or interferon-a), embolization and chemoembolization of liver metastases, chemotherapy (with single or multiple dose regimens) and peptide receptor-targeted radiotherapy. The delicate balance of the use of the different therapeutical options in patients with endocrine tumours of the gastrointestinal tract and pancreas emphasizes the importance of team approach and team expertise.

show abstract

“…3], and from case reports in humans describing effects as good as tumour regression in patients with metastatic endocrine GEP tumours [4][5][6][7][8][9][10][11], In addi tion, a recent NIH report analysing data from retro spective studies with 94 patients described partial tumour regression in 3%, stabilisation of the disease in 63% and tumour regression in 24%. However, the study population was heterogeneous and included patients with GEP tu mours of different origin [12].…”

Section: Long-acting Som Atostatin a N A Logu E Smentioning

confidence: 99%

Control of Growth in Neuroendocrine Gastro-Enteropancreatic Tumours

Arnold

Frank²

1996

Digestion

View full text Add to dashboard Cite

This paper reviews data on the effect of pharmacological anti-tumour agents on tumour growth in patients with malignant gastro-enteropancreatic (GEP) tumours. Agents include long-acting somatostatin analogues, interferon-α, a combination of both, chemotherapy, and chemo-embolisation. Characteristics of tumours are considered which should be taken into account in the management of patients with metastatic endocrine GEP tumours, including growth rate. Tumour type should be matched to the anti-proliferative strategy.

show abstract

Treatment of Metastasising GRF-Producing Tumour With a Long-Acting Somatostatin Analogue

Cited by 64 publications

References 5 publications

Management of Gastroenteropancreatic Endocrine Tumors: The Place of Somatostatin Analogues

Management of Gastroenteropancreatic Endocrine Tumors: The Place of Somatostatin Analogues

Considerations concerning a tailored, individualized therapeutic management of patients with (neuro)endocrine tumours of the gastrointestinal tract and pancreas.

Control of Growth in Neuroendocrine Gastro-Enteropancreatic Tumours

Contact Info

Product

Resources

About